Top

Annals of Nuclear Medicine

Published in:

01-03-2021 | Tremor | Original Article

Test–retest reproducibility of dopamine transporter density measured with [¹⁸F]FP-CIT PET in patients with essential tremor and Parkinson’s disease

Authors: Hye Joo Son, Jungsu S. Oh, Minyoung Oh, Sang Ju Lee, Seung Jun Oh, Sun Ju Chung, Jae Seung Kim

Published in: Annals of Nuclear Medicine | Issue 3/2021

Abstract

Objective

¹⁸F-labeled fluoropropyl-carbomethoxylodopropyl-nor-ß-tropane ([¹⁸F]FP-CIT) positron emission tomography (PET) is a useful tool for evaluating disease progression in Parkinson’s disease (PD) patients. We evaluated the test–retest reproducibility of [¹⁸F]FP-CIT PET measures in essential tremor (ET) and PD patients.

Methods

Fifteen ET (68.9 ± 6.6 years) and 10 PD patients (70.5 ± 6.3 years; Hoehn and Yahr stage, 2.3 ± 0.8) underwent two [¹⁸F]FP-CIT PET/CT scans with an interval of 48 ± 7 day. For both the test and retest studies, standardized uptake value ratios were estimated for 90-min and 3-h acquisitions for the caudate, anterior putamen, and posterior putamen using T1-MRI-based normalization (automatic) and fixed-VOI (manual) methods, with the occipital lobe as a reference. Reproducibility was evaluated by the bias, variability, percent test–retest, within-subject coefficient of variation, repeatability coefficient, and intraclass correlation coefficient (ICC).

Results

Reproducibility was excellent, with low variability (ET: 6.99–8.02%, PD: 3.51–6.94%) and high reliability (ICC; ET: 0.88–0.96, PD: 0.98–0.99). The ET group showed higher variability and lower ICCs than the PD group. The variability in the 90-min images (ET: 7.85–8.59%, PD: 1.52–2.75%) was comparable to that in the 3-h images (ET: 6.99–8.02%, PD: 3.51–6.94%). There were no differences in variability among the subregions in the ET group. In the PD group, the variability was high in the posterior putamen (automatic method: 6.94%, manual method: 11.80%). The test–retest variability and ICCs were similar for the manual and automatic methods.

Conclusion

[¹⁸F]FP-CIT PET is reproducible for the quantitative measurement of DAT binding in both ET and PD individuals, independent of the acquisition time or analysis method. Also, the automatic method is more suitable for evaluating early loss of DAT binding in patients with PD

Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, et al. Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med. 2013;368:610–22.CrossRef

Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68:384–6.CrossRef

Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003;39:889–909.CrossRef

Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125:861–70.CrossRef

Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181–4.CrossRef

Kim JS. Practical approach for the clinical use of dopamine transporter imaging. Nucl Med Mol Imaging. 2008;42:425–34.

Hirvonen J, Johansson J, Teräs M, Oikonen V, Lumme V, Virsu P, et al. Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility. J Cereb Blood Flow Metab. 2008;28:1059–69.CrossRef

Kaller S, Rullmann M, Patt M, Becker GA, Luthardt J, Girbardt J, et al. Test-retest measurements of dopamine D(1)-type receptors using simultaneous PET/MRI imaging. Eur J Nucl Med Mol Imaging. 2017;44:1025–32.CrossRef

Yeh CB, Chou YH, Cheng CY, Lee MS, Wang JJ, Lee CH, et al. Reproducibility of brain dopamine transporter binding with Tc-99m TRODAT-1 SPECT in healthy young men. Psychiatry Res. 2012;201:222–5.CrossRef

10.

Matsuoka K, Yasuno F, Shinkai T, Miyasaka T, Takahashi M, Kiuchi K, et al. Test-retest reproducibility of extrastriatal binding with (123)I-FP-CIT SPECT in healthy male subjects. Psychiatry Res Neuroimaging. 2016;258:10–5.CrossRef

11.

Kodaka F, Ito H, Kimura Y, Fujie S, Takano H, Fujiwara H, et al. Test-retest reproducibility of dopamine D2/3 receptor binding in human brain measured by PET with [11C]MNPA and [11C]raclopride. Eur J Nucl Med Mol Imaging. 2013;40:574–9.CrossRef

12.

Tsuchida T, Ballinger JR, Vines D, Kim YJ, Utsunomiya K, Lang AE, et al. Reproducibility of dopamine transporter density measured with 123I-FPCIT SPECT in normal control and Parkinson’s disease patients. Ann Nucl Med. 2004;18:609–16.CrossRef

13.

Hwang WJ, Yao WJ, Wey SP, Ting G. Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson’s disease. J Nucl Med. 2004;45:207–13.PubMed

14.

Deuschl G, Bain P, Brin M. Consensus statement of the movement disorder society on tremor. Ad hoc scientific committee. Mov Disord. 1998;13(Suppl 3):2–23.PubMed

15.

16.

Lee SJ, Oh SJ, Chi DY, Kang SH, Kil HS, Kim JS, et al. One-step high-radiochemical-yield synthesis of [18F]FP-CIT using a protic solvent system. Nucl Med Biol. 2007;34:345–51.CrossRef

17.

Baumgartner R, Joshi A, Feng D, Zanderigo F, Ogden RT. Statistical evaluation of test-retest studies in PET brain imaging. EJNMMI Res. 2018;8:13.CrossRef

18.

Barnhart HX, Barboriak DP. Applications of the repeatability of quantitative imaging biomarkers: a review of statistical analysis of repeat data sets. Transl Oncol. 2009;2:231–5.CrossRef

19.

Quan H, Shih WJ. Assessing reproducibility by the within-subject coefficient of variation with random effects models. Biometrics. 1996;52:1195–203.CrossRef

20.

Snedecor GW, Cochran WG. Specific indices of interater reliability. In: Snedecor GW, Cochran WG, editors. Statistical methods. Ames, IA: Iowa State University Press; 1989. p. 147–56.

21.

Seibyl JP, Marek K, Sheff K, Baldwin RM, Zoghbi S, Zea-Ponce Y, et al. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson’s patients. J Nucl Med. 1997;38:1453–9.PubMed

22.

Booij J, Habraken JB, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson’s disease. J Nucl Med. 1998;39:1879–84.PubMed

23.

Malison RT, Laruelle M, Innis RB. Positron and single photon emission tomography: principles and applications in psychopharmacology. In: Bloom FE, Kupfer DJ, editors. The fourth generation of progress. New York, NY: Raven Press; 1995. p. 865.

24.

Asenbaum S, Brücke T, Pirker W, Podreka I, Angelberger P, Wenger S, et al. Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson’s disease. J Nucl Med. 1997;38:1–6.PubMed

25.

Booij J, Hemelaar TG, Speelman JD, de Bruin K, Janssen AG, van Royen EA. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson’s disease by [123I]FPCIT SPECT. J Nucl Med. 1999;40:753–61.PubMed

26.

Kazumata K, Dhawan V, Chaly T, Antonini A, Margouleff C, Belakhlef A, et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med. 1998;39:1521–30.PubMed

27.

Alakurtti K, Johansson JJ, Joutsa J, Laine M, Bäckman L, Nyberg L, et al. Long-term test-retest reliability of striatal and extrastriatal dopamine D2/3 receptor binding: study with [(11)C]raclopride and high-resolution PET. J Cereb Blood Flow Metab. 2015;35:1199–205.CrossRef

28.

Egerton A, Demjaha A, McGuire P, Mehta MA, Howes OD. The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. Neuroimage. 2010;50:524–31.CrossRef

29.

Gibb WR. Neuropathology of Parkinson’s disease and related syndromes. Neurol Clin. 1992;10:361–76.CrossRef

30.

Suzuki M, Ito H, Kodaka F, Takano H, Kimura Y, Fujiwara H, et al. Reproducibility of PET measurement for presynaptic dopaminergic functions using L-[β-(11)C]DOPA and [(18)F]FE-PE2I in humans. Nucl Med Commun. 2014;35:231–7.CrossRef

31.

Yaqub M, Boellaard R, van Berckel BN, Ponsen MM, Lubberink M, Windhorst AD, et al. Quantification of dopamine transporter binding using [18F]FP-beta-CIT and positron emission tomography. J Cereb Blood Flow Metab. 2007;27:1397–406.CrossRef

32.

Gardiner SA, Morrison MF, Mozley PD, Mozley LH, Brensinger C, Bilker W, et al. Pilot study on the effect of estrogen replacement therapy on brain dopamine transporter availability in healthy, postmenopausal women. Am J Geriatr Psychiatry. 2004;12:621–30.CrossRef

Title: Test–retest reproducibility of dopamine transporter density measured with [18F]FP-CIT PET in patients with essential tremor and Parkinson’s disease
Authors: Hye Joo Son
Jungsu S. Oh
Minyoung Oh
Sang Ju Lee
Seung Jun Oh
Sun Ju Chung
Jae Seung Kim
Publication date: 01-03-2021
Publisher: Springer Singapore
Keywords: Tremor
Positron Emission Tomography
Parkinson's Disease
Published in: Annals of Nuclear Medicine / Issue 3/2021
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-020-01561-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Test–retest reproducibility of dopamine transporter density measured with [¹⁸F]FP-CIT PET in patients with essential tremor and Parkinson’s disease

Abstract

Objective

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2021

Clinical value of machine learning-based interpretation of I-123 FP-CIT scans to detect Parkinson’s disease: a two-center study

Test–retest repeatability of quantitative bone SPECT/CT

[18F]FDG PET/MRI in rectal cancer

Semi-quantitative assessment optimized the grading of pulmonary aspiration on salivagram in children

Diagnostic performance of 68Ga-DOTATOC PET/CT in tumor-induced osteomalacia

Clinical practice guidelines for high-resolution breast PET, 2019 edition